Deep and ongoing response of castrate-resistant prostate cancer on very low-dose enzalutamide in an elderly chemotherapy–naïve patient: a case report

BACKGROUND: Enzalutamide is an orally administered drug that blocks signaling in the androgen receptor with clinical activity in both chemotherapy–naive and post-chemotherapy patients with castrate-resistant prostate cancer (CRPC). Enzalutamide is generally well-tolerated, but dose reductions are no...

Descripción completa

Detalles Bibliográficos
Autores principales: Boerrigter, Emmy, Havenith, Thomas, van Erp, Nielka P., Schnog, John-John B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8149336/
https://www.ncbi.nlm.nih.gov/pubmed/33817752
http://dx.doi.org/10.1007/s00280-021-04269-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8149336/
https://www.ncbi.nlm.nih.gov/pubmed/33817752
http://dx.doi.org/10.1007/s00280-021-04269-3

Ejemplares similares